Niosomes encapsulating paclitaxel for oral bioavailability enhancement: preparation, characterization, pharmacokinetics and biodistribution

References

• Abdelbary G, El-Gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech, 2008;9:740–7
   PubMed Web of Science ®Google Scholar
• Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm, 2005;290:155–9
   PubMed Web of Science ®Google Scholar
• Azmin MN, Florence AT, Handjani-Vila RM, Stuart JF, Vanlerberghe G, Whittaker JS. The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol, 1985;37:237–42
   PubMed Web of Science ®Google Scholar
• Bayindir ZS, Yuksel N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci, 2010;99:2049–60
   PubMed Web of Science ®Google Scholar
• Choi JS, Jo BW. Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Int J Pharm, 2004;280:221–7
   PubMed Web of Science ®Google Scholar
• Cortesi R, Esposito E, Corradini F, Sivieri E, Drechsler M, Rossi A, Scatturin A, Menegatti E. Non-phospholipid vesicles as carriers for peptides and proteins: Production, characterization and stability studies. Int J Pharm, 2007;339:52–60
   PubMed Web of Science ®Google Scholar
• Cosco D, Paolino D, Muzzalupo R, Celia C, Citraro R, Caponio D, Picci N, Fresta M. Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5-fluorouracil. Biomed Microdevices, 2009;11:1115–25
   PubMed Web of Science ®Google Scholar
• Desai TR, Finlay WH. Nebulization of niosomal all-trans-retinoic acid: An inexpensive alternative to conventional liposomes. Int J Pharm, 2002;241:311–17
   PubMed Web of Science ®Google Scholar
• Domb AJ, Tabata Y, Ravi Kumar MNV, Farber S. 2007. Nanoparticles for pharmaceutical applications. In: Feng SS, Lee PPS, Win KY, eds. Nanoparticles of biodegradable polymers for cancer chemotherapy. Stevenson Ranch, CA: American Scientific, pp. 257–70
   Google Scholar
• Dong Y, Feng SS. Nanoparticles of poly(D,L-lactide)/methoxy poly(ethylene glycol)-poly(D,L-lactide) blends for controlled release of paclitaxel. J Biomed Mater Res A, 2006;78:12–19
   PubMed Web of Science ®Google Scholar
• Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J Cont Rel, 1990;11:205–14
   Web of Science ®Google Scholar
• Gianasi E, Cociancich F, Uchegbu IF, Florence AT, Duncan R. Pharmaceutical and biological characterisation of a doxorubicin-polymer conjugate (PK1) entrapped in sorbitan monostearate Span 60 niosomes. Int J Pharm, 1997;148:139–48
   Web of Science ®Google Scholar
• Helgason HH, Kruijtzer CM, Huitema AD, Marcus SG, ten Bokkel Huinink WW, Schot ME, Schornagel JH, Beijnen JH, Schellens JH. Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. Br J Cancer, 2006;95:794–800
   PubMed Web of Science ®Google Scholar
• Hu FQ, Ren GF, Yuan H, Du YZ, Zeng S. Shell cross-linked stearic acid grafted chitosan oligosaccharide self-aggregated micelles for controlled release of paclitaxel. Coll Surf B Biointer, 2006;50:97–103
   PubMed Web of Science ®Google Scholar
• Jadon PS, Gajbhiye V, Jadon RS, Gajbhiye KR, Ganesh N. Enhanced oral bioavailability of griseofulvin via niosomes. AAPS PharmSciTech, 2009;10:1186–92
   PubMed Web of Science ®Google Scholar
• Jain S, Singh P, Mishra V, Vyas SP. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B. Immunol Lett, 2005;101:41–9
   PubMed Web of Science ®Google Scholar
• Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. Br J Clin Pharmacol, 2005;59:325–34
   PubMed Web of Science ®Google Scholar
• Kim S, Kim JY, Huh KM, Acharya G, Park K. Hydrotropic polymer micelles containing acrylic acid moieties for oral delivery of paclitaxel. J Cont Rel, 2008;132:222–9
   PubMed Web of Science ®Google Scholar
• Kruijtzer CM, Boot H, Beijnen JH, Lochs HL, Parnis FX, Planting AS, Pelgrims JM, Williams R, Mathot RA, Rosing H, et al. Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. Ann Oncol, 2003;14:197–204
   PubMed Web of Science ®Google Scholar
• Kruijtzer CM, Schellens JH, Mezger J, Scheulen ME, Keilholz U, Beijnen JH, Rosing H, Mathot RA, Marcus S, van Tinteren H, Baas P. Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J Clin Oncol, 2002;20:4508–16
   PubMed Web of Science ®Google Scholar
• Li X, Choi JS. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. Int J Pharm, 2007;337:188–93
   PubMed Web of Science ®Google Scholar
• Luciani A, Olivier JC, Clement O, Siauve N, Brillet PY, Bessoud B, Gazeau F, Uchegbu IF, Kahn E, Frija G, et al. Glucose receptor MR imaging of tumors: Study in mice with PEGylated paramagnetic niosomes. J Radiol, 2004;231:135--42
   Google Scholar
• Malingre MM, Terwogt JM, Beijnen JH, Rosing H Koopman FJ, van Tellingen O, Duchin K, Huinink WW, Swart M, Lieverst J, et al. Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol, 2000;18:2468–75
   PubMed Web of Science ®Google Scholar
• Mukherjee B, Patra B, Layek B, Mukherjee A. Sustained release of aciclovir from nano-liposomes and nano-niosomes: An in vitro study. Int J Nanomed, 2007;2:213–25
   PubMed Web of Science ®Google Scholar
• Muramatsu M, Kanada K, Nishida A, Ouchi K, Saito N, Yoshida M, Shimoaka A, Ozeki T, Yuasa H, Kanaya Y. Application of Carbopol to controlled release preparations I. Carbopol as a novel coating material. Int J Pharm, 2000;199:77–83
   PubMed Web of Science ®Google Scholar
• Naresh RA, Udupa N, Umadevi P. Niosomal plumbagin with reduced toxicity and improved anticancer activity in Balb/c Mice. J Pharm Pharmacol, 1996;48:1128–32
   PubMed Web of Science ®Google Scholar
• Nasr M, Mansour S, Mortada ND, Elshamy AA. Vesicular aceclofenac systems: A comparative study between liposomes and niosomes. J Microencap, 2008;25:499–512
   PubMed Web of Science ®Google Scholar
• Nornoo AO, Zheng H, Lopes LB, Johnson-Restrepo B, Kannan K, Reed R. Oral microemulsions of paclitaxel: In situ and pharmacokinetic studies. Eur J Pharm Biopharm, 2009;71:310–17
   PubMed Web of Science ®Google Scholar
• Ozeki T, Yuasa H, Okada H. Controlled release of drug via methylcellulose-carboxyvinylpolymer interpolymer complex solid dispersion. AAPS PharmSciTech, 2005;6:E231–6
   PubMed Web of Science ®Google Scholar
• Panchagnula R. Pharmaceutical aspects of paclitaxel. Int J Pharm, 1998;172:1–15
   Web of Science ®Google Scholar
• Pang KS. Modeling of intestinal drug absorption: Roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos, 2003;31:1507–19
   PubMed Web of Science ®Google Scholar
• Paolino D, Cosco D, Muzzalupo R, Trapasso E, Picci N, Fresta M. Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int J Pharm, 2008;353:233–42
   PubMed Web of Science ®Google Scholar
• Pardakhty A, Varshosaz J, Rouholamini A. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm, 2007;328:130–41
   PubMed Web of Science ®Google Scholar
• Parmentier J, Becker MM, Heintz U, Fricker G. Stability of liposomes containing bio-enhancers and tetraether lipids in simulated gastro-intestinal fluids. Int J Pharm, 2011;405:210–17
   PubMed Web of Science ®Google Scholar
• Parthasarathi G, Udupa N, Parameshwaraiah N, Pillai GK. Altered biological distribution of decreased neuromuscular toxicity of niosome encapsulated vincristine. Ind J Exp Bio, 1996;34:124–30
   PubMedGoogle Scholar
• Peltier S, Oger JM, Lagarce F, Couet W, Benoit JP. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res, 2006;23:1243–50
   PubMed Web of Science ®Google Scholar
• Sezgin-Bayindir Z, Yuksel N. Investigation of formulation variables and excipient interaction on the production of niosomes. AAPS PharmSciTech, 2012;13:826–35
   PubMed Web of Science ®Google Scholar
• Shi B, Fang C, Pei Y. Stealth PEG-PHDCA niosomes: Effects of chain length of PEG on niosomes in vitro complement consumption and phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J Pharm Sci, 2006;95:1873–87
   PubMed Web of Science ®Google Scholar
• Shin BS, Kim HJ, Hong SH, Lee JB, Hwang SW, Lee MH, Yoo SD. Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form. Cancer Chem Pharmacol, 2009;64:87–94
   PubMed Web of Science ®Google Scholar
• Singla AK, Garg A, Aggarwal A. Paclitaxel and its formulations. Int J Pharm, 2002;235:179–92
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Matsui Y, Yamamoto H, Kawashima Y. Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J Cont Rel, 2003;86:235–42
   PubMed Web of Science ®Google Scholar
• Uchegbu IF, Duncan R. Niosomes containing N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin (PK1): Effect of method of preparation and choice of surfactant on niosome characteristics and a preliminary study of body distribution. Int J Pharm, 1997;155:7–17
   Web of Science ®Google Scholar
• Varshosaz J, Pardakhty A, Hajhashemi VI, Najafabadi AR. Development and physical characterization of sorbitan monoester niosomes for insulin oral delivery. Drug Del, 2003;10:251–62
   PubMed Web of Science ®Google Scholar
• Veltkamp SA, Rosing H, Huitema AD, Fetell MR, Nol A, Beijnen JH, Schellens JH. Novel paclitaxel formulations for oral application: A phase I pharmacokinetic study in patients with solid tumours. Cancer Chem Pharmacol, 2007;60:635–42
   PubMed Web of Science ®Google Scholar
• Veltkamp SA, Thijssen B, Garrigue JS, Lambert G, Lallemand F, Binlich F, Huitema AD, Nuijen B, Nol A, Beijnen JH, et al. A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. Br J Cancer, 2006;95:729–34
   PubMed Web of Science ®Google Scholar
• Venkatesan N, Vyas SP. Polymer-coated vesicles: Development and characterization. Drug Del, 1998;5:251–5
   PubMed Web of Science ®Google Scholar
• Werle M, Makhlof A, Takeuchi H. Carbopol-lectin conjugate coated liposomes for oral peptide delivery. Chem Pharm Bull, 2010;58:432–4
   PubMed Web of Science ®Google Scholar
• Yang H, Deng A, Zhang J, Wang J, Lu B. Preparation, characterization and anticancer therapeutic efficacy of cisplatin-loaded niosomes. J Microencapsul, 2013;30(3):237--44
   Google Scholar
• Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, Shim CK, Kim DD. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Cont Rel, 2007a;120:169–77
   PubMed Web of Science ®Google Scholar
• Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD. Enhanced solubility and stability of PEGylated liposomal paclitaxel: In vitro and in vivo evaluation. Int J Pharm, 2007b;338:317–26
   PubMed Web of Science ®Google Scholar
• Zhang Z, Feng SS. Self-assembled nanoparticles of poly(lactide)–Vitamin E TPGS copolymers for oral chemotherapy. Int J Pharm, 2006;324:191–8
   PubMed Web of Science ®Google Scholar